Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Author:

Shao Zhimin1,Pang Da2,Yang Hongjian3,Li Wei4,Wang Shusen5,Cui Shude6,Liao Ning7,Wang Yongsheng8,Wang Chuan9,Chang Yuan-Ching10,Wang Hweichung11,Kang Seok Yun12,Seo Jae Hong13,Shen Kunwei14,Laohawiriyakamol Suphawat15,Jiang Zefei16,Li Junjie1,Zhou Julian17,Althaus Betsy18,Mao Yixiang1920,Eng-Wong Jennifer18

Affiliation:

1. Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

2. Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China

3. Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, China

4. Medicine–Oncology, The First Hospital of Jilin University, Changchun, China

5. Medicine–Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

6. Department of Breast Disease, Henan Cancer Hospital, Zhengzhou, China

7. Department of Breast Disease, Guangdong General Hospital, Guangzhou, China

8. Breast Disease Center, Shandong Cancer Hospital, Jinan, China

9. Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China

10. Department of General Surgery, Mackay Memorial Hospital, Taipei City, Taiwan

11. Department of Surgery, China Medical University Hospital, Taichung City, Taiwan

12. Department of Hematology–Oncology, Ajou University School of Medicine, Suwon, Republic of Korea

13. Division of Oncology/Hematology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea

14. Breast Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

15. Department of Surgery, Songklanagarind Hospital, Songkhla, Thailand

16. Medicine–Oncology, The Affiliated Hospital of Military Medical Sciences (The 307th Hospital of Chinese People’s Liberation Army), Beijing, China

17. Biometrics, Roche Product Development, Shanghai, China

18. Product Development Oncology, Genentech, Inc, South San Francisco, California

19. Roche Product Development, Shanghai, China

20. now at Oncology Clinical Research, Merck Sharp & Dohme China, Shanghai, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3